IRVINE, Calif., June 27, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today debuted Allē Payment Plans, powered by Cherry. By giving consumers the power to pay over-time for aesthetic treatments and products, including BOTOX® Cosmetic (onabotulinumtoxinA) and the JUVÉDERM® Collection of Fillers, Allē Payment Plans make aesthetics more accessible and affordable.
Market research shows more than 50 million Americans are interested in facial injectables, but only a fraction seek treatment each year, citing cost as the biggest barrier1. Now, with Allē Payment Plans, patients can pay for their treatments with a monthly plan making it easier for them to achieve their aesthetic goals.
"We are excited to debut flexible payment plans within Allē at no cost* to aesthetic practices for Allergan Aesthetics treatments and products, increasing the accessibility and affordability of aesthetic treatments for patients and supporting providers to welcome new patients," said Jasson Gilmore, Senior Vice President, U.S. Aesthetics. "Over the last several years, pay over-time solutions have grown to become a preferred method of payment for millions of Americans from cell phones to clothing. Allē Payment Plans help patients pursue the recommended treatments they want, on terms that work for them."
Allē Payment Plans initial pilot program uncovered key insights. "We found that 54% of transactions were from patients new to aesthetics or trying a new service. 34% of transactions included two or more brands2," shared Jasson Gilmore. "This shows that consumers want to pay over-time for the recommended aesthetic treatments they have been considering. Removing cost as a barrier gives them that opportunity."
The Allē Payment Plans national roll-out begins today, with full availability across the U.S. expected over the next few months. "Our practice began accepting Allē Payment Plans as part of a pilot program. Since then, we've seen an influx of patients who want to pay over-time and are now interested in learning about additional treatments to help achieve their aesthetic goals," said Neekan Rivera, PA, Allergan Medical Institute Trainer and founder of Aère Aesthetics. "Allē Payment Plans quickly became a seamless part of our front desk experience, and our patients earn Allē points for their treatments."
"We are thrilled to partner with Allergan Aesthetics, the market leader, given their industry defining products and their success with Allē, the country's leading aesthetics loyalty rewards platform," said Sean Schroeder, COO at Cherry. "With Cherry's years of experience in patient financing, and Allē's leadership in aesthetics rewards, this combined offering will support practices in helping make aesthetics treatments more accessible for all."
Allē is offering an inside look of Allē Payment Plans to providers attending The Aesthetic Show (TAS) in Las Vegas, Nev., June 27-June 30, 2024. Attendees can join a sponsored Lunch and Learn and can also schedule personalized one-on-one discussions with an Allergan Digital Consultant at the Allergan Aesthetics booth to discover how to optimize Allē for Business within their practice and to prepare for Allē Payment Plans.
In serving more than seven million Members across ~30,000 practices to date, part of Allē's mission is to help educate consumers about aesthetic treatments, and to simplify office operations for practices. From its inception, Allē has disrupted the aesthetics industry by offering the most robust rewards program. Allē is the first and only loyalty program in the aesthetics market to also offer consumers the ability to earn points on over 50 non-Allergan Aesthetics treatments and brands. By providing Members with information, tools, and incentives, and now with flexible ways to pay, Allē empowers consumers along their treatment journey, making the next product purchase or treatment closer within reach.
To learn more about offering Allē Payment Plans in your practice, please reach out to your Allergan Aesthetics sales representative, or visit http://business.alle.com/payment-plans for more information.
*Payouts in full are for eligible Allergan Aesthetics products and treatments only. All other services are subject to standard Cherry rates.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
About Cherry
Cherry's mission is to help medical providers treat more patients by offering the best payment plan solution with high approvals, low cost, and a seamless experience. With leading financing terms for practices and patients, Cherry is the preferred partner for over 20,000 practices in aesthetics, dental and beyond. For more information, visit www.withcherry.com.
BOTOX® COSMETIC IMPORTANT SAFETY INFORMATION AND APPROVED USES
Approved Uses
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:
BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines.
BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.
Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.
Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes.
For more information refer to the Medication Guide or talk with your doctor.
To report a side effect, please call Allergan at 1-800-678-1605.
Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide.
JUVÉDERM® Injectable Gel Fillers Important Information
APPROVED USES
JUVÉDERM® VOLUX® XC injectable gel is for deep injection to improve moderate to severe loss of jawline definition in adults over the age of 21.
JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile in adults over 21.
JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC injectable gels are for injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. JUVÉDERM® VOLLURE® XC injectable gel is for adults over 21.
JUVÉDERM® Ultra XC injectable gel is also for injection into the lips and perioral area for lip augmentation in adults over 21.
JUVÉDERM® VOLBELLA® XC injectable gel is for injection into the lips for lip augmentation and correction of perioral lines, and for injection into the undereye hollows to improve the appearance of undereye hollows in adults over the age of 21.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive any JUVÉDERM® formulation?
Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), if you are allergic to lidocaine or the Gram-positive bacterial proteins used in these products, or if you have had previous allergic reactions to hyaluronic acid fillers.
What warnings should my doctor advise me about?
What precautions should my doctor advise me about?
What are possible side effects of treatment?
The most commonly reported side effects with JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported.
These side effects are consistent with other facial injection procedures and most will resolve within 30 days. Your doctor may choose to treat side effects persisting longer with antibiotics, steroids, or hyaluronidase (an enzyme that breaks down hyaluronic acid).
As with all skin injection procedures, there is a risk of infection.
To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 18773455372. Please also visit Juvederm.com or talk to your doctor for more information.
Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.
References:
Last Trade: | US$167.95 |
Daily Change: | 1.38 0.83 |
Daily Volume: | 4,240,556 |
Market Cap: | US$297.270B |
November 18, 2024 October 31, 2024 October 30, 2024 October 28, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB